Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sternum-worn vibrotactile device in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot trial.

NPJ Parkinson's disease·2026
Same author

Regional Variations in Mortality, Surgical Treatment, and Hospitalization in Children With Congenital Diaphragmatic Hernia: A European Population-Based Data-Linkage Cohort Study.

Birth defects research·2026
Same authorSame journal

Response to Takahashi regarding Bestwick and Wald: Mischaracterisation of evidence in prostate cancer screening.

Journal of medical screening·2026
Same author

Screening for prostate cancer.

Journal of medical screening·2026
Same author

Children With Biliary Atresia Have Substantial Morbidity in Early Childhood and a High Risk of Liver Transplantation.

Birth defects research·2026
Same author

Simplifying and improving heart attack and stroke prevention.

Lancet (London, England)·2026
Same journal

Cost-benefit analysis of an organized community-based multi-cancer screening program in Bangladesh.

Journal of medical screening·2026
Same journal

Response to: Adjusting for non-compliance and contamination with a more plausible assumption.

Journal of medical screening·2026
Same journal

No-cost envelope modification improves fecal immunochemical test laboratory acceptance in a US Veterans Affairs colorectal cancer screening trial.

Journal of medical screening·2026
Same journal

Prostate cancer screening: The level of the evidence hierarchy.

Journal of medical screening·2026
Same journal

Prediction model to prioritize colorectal cancer screening with visual colonoscopy.

Journal of medical screening·2026
See all related articles

Related Experiment Video

Updated: Oct 1, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Multi-marker risk-based screening for prostate cancer.

Nicholas J Wald1,2, Jonathan P Bestwick3, Joan K Morris2

  • 1Institute of Health Informatics, 4919University College London, London, UK.

Journal of Medical Screening
|March 7, 2022
PubMed
Summary
This summary is machine-generated.

A new prostate cancer screening method combining age, total PSA, and hK2 markers significantly improves detection rates while reducing false positives compared to PSA alone. This multi-marker approach aims to decrease overdiagnosis and overtreatment in men aged 55 and older.

Keywords:
Prostate cancerhuman kallikrein-related peptidase 2prostate specific antigenscreening

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

412
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.7K

Related Experiment Videos

Last Updated: Oct 1, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

412
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.7K

Area of Science:

  • Urology
  • Oncology
  • Biomarker Research

Background:

  • Prostate cancer screening commonly uses prostate-specific antigen (PSA).
  • Current PSA screening methods face challenges with specificity and overdiagnosis.
  • Novel multi-marker approaches are needed to enhance prostate cancer detection accuracy.

Purpose of the Study:

  • To evaluate the screening performance of PSA combined with other biomarkers.
  • To express marker levels as age-specific multiples of the median (MoM).
  • To develop a risk-based algorithm for improved prostate cancer screening.

Main Methods:

  • A prospective nested case-control study involving 571 prostate cancer cases and 2169 controls.
  • Measurement of total, free, and intact PSA, human kallikrein-related peptidase 2 (hK2), and microseminoprotein.
  • Utilized Monte Carlo simulation with a risk-based algorithm to estimate detection rates (DRs) and false-positive rates (FPRs).

Main Results:

  • Combining age, total PSA MoM, and hK2 MoM achieved a 90% DR with a 1.2% FPR.
  • This multi-marker approach demonstrated a two-thirds reduction in FPR compared to PSA alone (4.5% FPR for 90% DR).
  • Screening over 10 years with the algorithm yielded a 33% FPR for a 90% DR.

Conclusions:

  • A multi-marker, risk-based screening algorithm using age, total PSA, and hK2 offers superior performance over PSA alone.
  • This enhanced screening strategy can significantly lower false-positive rates, reducing overdiagnosis and overtreatment.
  • The proposed method supports more effective prostate cancer screening from age 55 onwards.